ABSTRACT
INTRODUCTION
New international guidelines suggest to administer a single course of antenatal corticosteroids (ACS) to pregnant women between 24 +0 weeks and 33 +6 weeks of gestation who are at risk of preterm delivery within 7 days 1) . In neonates whose mothers received ACS, a low incidence of respiratory distress syndrome (RDS) has been reported with a reduction of intraven tricular hemorrhage (IVH), necrotizing enterocolitis (NEC), duration of mechanical ventilation, systemic infections in the first 48 hours after birth, and overall neonatal death 2, 3) . Although ACS treatment less than 24 hours from birth is still associated with reduced neonatal mortality and morbidities in preterm infants, ACS treatment is known to be most beneficial at 2 to 7 days after the initial dose 1, 4) .
Although beneficial effects of ACS have been established in singleton preterm infants, there are controversies on the beneficial effects of ACS use on neonatal outcomes in specific neo natal or maternal conditions such as multiple gestation, premature rupture of membranes, and intrauterine growth restriction (IUGR). Recently, many reports have supported the use of ACS between 24 +0 weeks and 33 +6 weeks age of gesta tion in multifetal gestations and in mothers with ruptured mem branes 1, 5) .
However, in infants with IUGR, there are still contro versies about the effectiveness of ACS on neonatal outcomes.
Regarding the efficacy of ACS on the neonatal outcomes of IUGR infants, there have been many studies on small for gestational age (SGA) neonates [6] [7] [8] ; however, there is still no clear consensus on intrauterine growth restricted infants. Some large population studies demonstrated decreased risks of neo natal death and RDS 9, 10) ; however, other studies showed no differ ence [11] [12] [13] .
SGA overlaps IUGR, but they do not coincide with each other 14) .
It is one of the reasons why we are unable to obtain clear results about the effect of ACS on neonatal outcomes in IUGR preterm infants.
The aim of this study was to investigate whether IUGR preterm infants can benefit from ACS administration as normally grown neonates.
MATERIALS AND METHODS

Study design
We retrospectively analyzed the medical records and perina- 15) , IVH ≥grade 3 of Papile's classification 16) , hypotension within 7 days from birth, inhaled nitric oxide (iNO) use within 14 postnatal days, relative adrenal insufficiency requiring hydrocortisone treatment, moderate to severe bronchopulmonary dysplasia (BPD), retinopathy of prematurity requiring treatment, discharge with respiratory support, and hospital stay.
Definitions
IUGR was defined as any fetal growth restriction (estimated fetal weight <10th percentile) documented from serial maternal medical records or a birth weight of less than the 10th percentile based on the growth curve of Olsen et al. 17) with absent or reverse umbilical artery end-diastolic flow in the fetal Doppler studies. If the organisms were identified after 3 or more postnatal days, it was defined as late onset sepsis. In the AGA without IUGR infants, multivariate logistic analysis was done after adjusting for PIH and uncontrolled pre term labor. In the IUGR infants, multivariate logistic regres sion was done after adjusting for birth weight and 5-minute Apgar score.
Statistical analysis
All analyses were performed with R version 3.1.2 (http://www. r-project.org) with the statistical significance set at a P-value of <0.05.
RESULTS
A total of 340 neonates were included. Among them, 91 (26.8%) of them were intrauterine growth restricted infants ( Figure 1 with 34 infants (13.7%). In the IUGR infants, the complete ACS group consisted of 40 infants (43.9%), the incomplete ACS group with 43 infants (47.3%), and the no ACS group with eight infants (8.8%). There was no significant difference in the proportion of complete, incomplete, and no ACS groups in both the AGA without IUGR and IUGR infants (P= 0.271).
Demographic and baseline characteristics
When comparing the demographic characteristics between the complete ACS, incomplete ACS, and no ACS groups, there were no significant differences in the AGA without IUGR infants.
The frequency of maternal PIH and uncontrolled preterm labor were different between the complete ACS, incomplete ACS, and no ACS groups with marginal significance (P=0.088 and P=0.065).
However, in the IUGR group, the birth weight and 5-minute Apgar score of the incomplete ACS group were significantly lower than those of the complete ACS group (Table 1) .
Mortality and in-hospital outcome
In the AGA without IUGR infants, the mortality was lower in the complete ACS group (2.2%) and in the incomplete ACS group (4.0%) when compared with the no ACS group (11.8%); however, they only showed a statistically marginal significance in the univariate analysis. Among the neonatal morbidities, hypotension within 7 postnatal days was significantly lower in the complete ACS group when compared with the no ACS group (6.7 % vs. 26.5%, P=0.012) ( Table 2 ).
In the IUGR infants, there were no significant differences in mortality and neonatal morbidities between the complete ACS, incomplete ACS, and no ACS groups in the univariate analysis (Table 2 ).
In the AGA without IUGR infants, multivariate logistic regression analysis, after adjusting for the maternal PIH and uncontrolled preterm labor, showed that the mortality was signi- Table 3 ).
In the IUGR group, multivariate analysis, after adjusting for birth weight and Apgar score at 5 minutes, showed that only the frequency of iNO within 14 days after birth was statistically significantly lower in both the complete ACS group (aOR, 0.07; 95% CI, 0.01 to 0.67) and the incomplete ACS group (aOR, 0.04; 95% CI, 0.01 to 0.37) when compared with the no ACS group (Table 3) .
DISCUSSION
This retrospective cohort study suggests that administering ACS to IUGR infants does not improve the overall neonatal mortality and major morbidities, except for iNO use within 14 postnatal days. However, in AGA infants, ACS appears to reduce death before discharge, severe BPD and/or death, and hy potension that occurred within 7 days after birth, requiring mana gement with inotropes.
Unlike previous reports about the effect of ACS on neonatal Elevated endogenous corticosteroid levels in IUGR is one of the reasons why many studies, including our study, revealed that ACS has no beneficial effect on IUGR 19, 20) . Intrauterine growth restricted fetuses are under stress of malnutrition and hypoxemia due to placental insufficiency 14) , and cortisol production is stimulated by fetal adrenal gland. In addition to this, the expression and activity of 11-beta-hydroxysteroid dehydrogenase type II (11-βHSD II) is reduced in IUGR, and this leads to less conversion of cortisol to cortisone, which induces excessive fetal exposure to maternal endogenous corticosteroids 21, 22) . For IUGR fetuses, exo genous administration of ACS can introduce exaggerated expo sure to corticosteroid, and this may cause adverse effects on fetal hypothalamo-pituitary-adrenal (HPA) axis programming and lung maturation. In animal model study, repetitive doses of corticosteroids lowered lung and liver weight 23) and induced hypertension 24) . Others showed that chronic intrauterine stress may also accelerate pulmonary maturation, resulting in a lower risk of RDS in IUGR infants rather than in AGA neonates 25) . There are still controversies about the effect of exogenous corticosteroids on lung growth and surfactant protein expression in the IUGR animal model 23) .
There are conflicting results about the efficacy of ACS in improving preterm neonatal outcomes for SGA infants. Riskin- 
P<0
.05 when compared with no ACS. Abbreviations: ACS, antenatal corticosteroid; AGA, appropriate for gestational age; IUGR, intrauterine growth restriction; aOR, adjusted odds ratio; CI, confidence intervals; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; iNO, inhaled nitric oxide; BPD, bronchopulmonary dysplasia.
Mashiah et al. 26) , using the Israel neonatal network database, reported that ACS decreased mortality and composite adverse outcomes. In a study using the Canadian neonatal network, a complete course of ACS use in SGA neonates decreased death, any mechanical ventilation, severe brain injury, and composite outcomes 7) . However, many other studies showed no significant differences in the neonatal outcomes of IUGR infants 27) . A population-based study, using a large cohort, classified their study population according to the presence of SGA, less than 10th percentile birth weight, and non-usage of maternal data or fetal ultra sonography. According to McGillick et al. 28) review, many of the studies on ACS use in infants with fetal growth restriction defined fetal growth restriction as a birth weight of <10th percentile. The main strength of our study is that we defined IUGR more accurately using maternal medical records and umbilical artery Doppler studies, and not just birth weight of <10th per centile alone.
We also categorized ACS use as complete and incomplete IUGR was shown to induce vasodilation, which increases blood flow to the major organs such as the heart and the brain, through several animal experiements 30) . Early pulmonary hypertension is often related to RDS and BPD. Though the RDS rate showed no significant difference in ACS treated infants, ACS treatment and use of a surfactant may lower the severity of PPHN 31) . Moreover, this may have an effect on the long-term outcome such as the duration of mechanical ventilator use, which was not included in our study.
There are several limitations in our study. First, this is a retrospective study with a small number of study subjects. If the analyses had been done with a larger number of subjects, the outcomes in the IUGR neonates that showed a marginal significance such as the neonatal death rate in the complete ACS group and the RDS and moderate to severe BPD or death rate in the incomplete ACS group could have been lower than those in the no ACS group. Second, we did not analyze the long-term outcomes such as neurological developments in each group. There are also conflicting results on ACS and brain development. Some cumulative evidence suggests that brain injury is asso ciated with ACS use in IUGR, which is caused by oxidative stress and cere bral reperfusion 10, 21) . Others have observed that there are no long-term neurological benefits from ACS use 6, 32) . To clarify the neurological effect of ACS, neurological follow-up data assessed by various tools should be analyzed.
In our study, both complete and incomplete ACS treatments did not reduce mortality or major morbidities in IUGR infants, except for early iNO use. Although there was no adverse effect from the ACS treatment on the neonatal outcomes in the IUGR infants, we should take careful consideration in giving ACS to IUGR fetus. In addition to this, a randomized controlled trial with a multicenter, large cohort study is needed to clarify the benefits and adverse effects of ACSs in IUGR.
